Medical Licensing (MD/DO) · Independent exam preparation
EBSQ Surgical Oncology: Clinical Decisions and Evidence Appraisal Study Guide
Practise margin decisions, cancer staging, multimodal sequencing and trial appraisal across EBSQ Surgical Oncology domains, with cases and focused recall.
By CertMedbry · Updated 19 October 2026
Decide when a margin needs further surgery, distinguish staging from treatment benefit, select patients for major oncological procedures, and interpret clinical research. This selective guide develops specialist reasoning across all seven written subject areas. The official UEMS examination outline and associated curricula define the full scope; these selected concepts do not exhaust it.
Try 20 free practice questionsWhat is the exam format?
Check the question types, timing and outline before planning your revision.
Which qualification and candidate level does this guide address?
This guide addresses EBSQ-Surgical Oncology, organized through the UEMS Section of Surgery Division of Surgical Oncology under European Board of Surgery authority, in cooperation with ESSO. Its standard is that of a fully qualified cancer specialist surgeon, with broad multidisciplinary knowledge and advanced expertise in the candidate's specialist discipline. Passing the written and oral examinations leads to the FEBS in Surgical Oncology diploma. It is a specialist qualification rather than a general medical licensing examination.
UEMS Section of Surgery — Surgical Oncology · UEMS — Surgical Oncology EBSQ Examination
How many written questions are there, and how are they delivered?
For 2026, Part A contains 60 single-best-answer MCQs, each with five options, over 120 minutes. Delivery is online, and all candidates answer the same questions; this is a fixed examination rather than an adaptive test. Wrong answers receive no negative points. The published information does not identify a separate scored/pretest question split.
What does the oral examination assess?
Part B consists of four 15-minute tasks: two clinical case discussions and appraisal of two clinical research papers. The papers are supplied one hour before the examination and may be taken into it. Candidates must first pass the written examination. Clinical reasoning, justification of management and interpretation of research therefore need explicit practice alongside factual recall.
Can candidates restrict preparation to their declared specialist areas?
The written examination covers all seven listed areas. Candidates declare three specialist areas during registration, and examiners select two of these to focus the oral examination. Other UEMS divisions offer separate discipline-specific EBSQ examinations; those examinations are outside this guide's chosen Surgical Oncology pathway.
UEMS — Surgical Oncology EBSQ Examination · UEMS Section of Surgery — Surgical Oncology
Which curriculum dates and blueprint weights apply?
The official 2026 examination lists seven written subject areas without percentage weights or a formal blueprint effective date. ESSO identifies its 2021 Core Curriculum update as preparation for EBSQ. UEMS states that examination subjects have more recently aligned with the joint ESSO–SSO global curriculum, but does not establish an adoption date for its specific 2026 revision. The UEMS syllabus page retains a historical 2013 link. The 2021 article's 2025 upload path does not change its publication date of 13 October 2021.
UEMS — Surgical Oncology EBSQ Examination · UEMS Section of Surgery — Surgical Oncology · UEMS — Surgical Oncology Curriculum and Syllabus · ESSO — Core Curricula · The ESSO core curriculum committee update on surgical oncology
How is coverage allocated in this guide and its practice test?
Without published domain percentages, coverage is editorial rather than an official weighting. The guide contains nine concepts each for Breast, Melanoma/Skin/Endocrine, Colorectal/Peritoneal Surface Malignancies and Hepato/Pancreatico/Biliary, and eight each for Upper GI, Sarcoma and General Oncology. The questions and flashcards each allocate three items to every domain except Upper GI, which receives two. The 20 four-option questions are independent learning drills; they neither reproduce the official five-option format nor simulate the oral examination or predict passing.
Is there a fixed passing percentage?
UEMS states that the written pass mark changes annually and is set before the examination using an Angoff standard-setting procedure. There is no single guaranteed passing percentage to target. Both written and oral parts must be passed for the diploma.
How do language and German ACO arrangements affect this pathway?
The 2026 page lists English, German, Spanish, French, Italian, Portuguese and Dutch, with the same examination content, course and eligibility criteria. Low oral candidate numbers in a language may lead to an offer of English or postponement. Eligible German ACO members who completed the specified one-year German Surgical Oncology fellowship can receive both UEMS and ACO certificates; other successful German-language candidates receive the UEMS certificate. This guide addresses the shared UEMS qualification.
What establishes eligibility and geographical applicability?
The qualification assesses specialist surgeons against European standards, and surgeons trained outside Europe may apply. Eligibility involves a current surgical licence, completed specialist training, qualifying surgical oncology experience, departmental support and a signed operative logbook. The official page specifies several experience routes and the required documents. National permission to practise remains a separate regulatory matter.
UEMS — Surgical Oncology EBSQ Examination · UEMS Section of Surgery — Surgical Oncology
Independent educational material for the European Board of Surgery Qualification in Surgical Oncology, leading to FEBS in Surgical Oncology. Clinical references support management principles; UEMS and ESSO sources establish examination identity and scope.
Outline used: 2026 UEMS examination outline, checked 2026-10-10; supported by the ESSO Core Curriculum update published online 2021-10-13 and still identified by ESSO as its EBSQ preparation curriculum. UEMS explicitly states that examination subject areas have more recently aligned with the joint ESSO–SSO global curriculum. This does not establish an examination adoption date for the specific 2026 global revision. No formal blueprint effective date or percentage weights are stated. The workbook label maps to this official examination; the assigned slug is preserved.
60 key concepts: understand, apply and avoid the traps
Work through the questions by exam domain. Explain the answer in your own words, try the example, then check the common pitfall.
Breastnot stated
1.What margin is adequate for invasive breast cancer?
For invasive breast carcinoma treated with breast-conserving surgery and whole-breast irradiation, an adequate negative margin is no ink on invasive cancer or associated DCIS. Once this standard is achieved, routinely obtaining wider microscopic clearance does not further improve local control. Tumour on ink generally warrants further surgery because residual disease risk is higher. Interpret the pathology alongside specimen orientation, imaging concordance and the planned radiation treatment.
Apply it
A patient has an invasive ductal carcinoma removed with a 1 mm clear margin and will receive whole-breast irradiation. Confirm that neither invasive carcinoma nor associated DCIS touches ink before recommending any further excision.
Common pitfall: Applying a routine 2 mm requirement to invasive carcinoma confuses its margin standard with the standard used for pure DCIS receiving whole-breast irradiation.
ASBrS — Resource Guide on Breast Cancer Breast Conservation Surgery Margins
2.How do pure DCIS margins guide further surgery?
For pure ductal carcinoma in situ treated with breast-conserving surgery and whole-breast irradiation, a 2 mm negative margin is the usual adequacy standard. Wider negative margins are not routinely necessary. A negative margin below 2 mm requires clinical judgment rather than automatic mastectomy: consider residual calcifications, disease extent, which margin is close, and whether further excision would remove meaningful breast tissue or only skin or fascia.
Apply it
A patient has pure DCIS with a 1 mm superior margin and persistent adjacent calcifications. Review radiology and specimen orientation; the combination suggests possible residual disease and supports considering directed re-excision before radiotherapy.
Common pitfall: A close negative margin and tumour on ink are different findings. Neither a sub-2 mm margin nor DCIS alone automatically requires mastectomy.
ASBrS — Resource Guide on Breast Cancer Breast Conservation Surgery Margins
3.When does Z0011 support omitting axillary dissection?
ACOSOG Z0011 supports omission of completion axillary lymph node dissection in its studied setting: clinically node-negative T1–T2 invasive breast cancer, one or two positive sentinel nodes, breast-conserving surgery, planned tangential whole-breast irradiation and adjuvant systemic treatment. Long-term overall survival with sentinel node surgery alone was noninferior. Eligibility features matter because irradiation and systemic therapy contribute to disease control; the result cannot be transferred indiscriminately to other treatment pathways.
Apply it
A patient with a 1.8 cm invasive tumour has no palpable axillary nodes and two positive sentinel nodes after lumpectomy. With planned whole-breast irradiation and systemic therapy, discuss omission of completion dissection using Z0011 eligibility.
Common pitfall: Do not assume that a mastectomy patient, clinically bulky nodal disease or residual nodal disease after neoadjuvant therapy represents the original Z0011 population.
JAMA — ACOSOG Z0011 randomized clinical trial: 10-year overall survival
4.How does sentinel node biopsy stage breast cancer?
Sentinel node biopsy identifies the first draining regional lymph nodes using lymphatic mapping, allowing pathological assessment with less axillary surgery than a full dissection. Its main function is staging, which can influence regional and systemic treatment decisions. Suitability depends on clinical nodal status and treatment context. A suspicious palpable or imaging-detected node may require needle sampling, because an already involved axilla poses a different decision from routine clinically node-negative staging.
Apply it
A patient with a small invasive breast tumour has a normal axillary examination but a morphologically suspicious node on ultrasound. Obtain targeted needle assessment of that node before treating the axilla as straightforward clinically node-negative disease.
Common pitfall: Lymphatic mapping identifies drainage, not freedom from metastasis. A sentinel node still requires pathological examination, and failed mapping does not establish negative nodal status.
NCI — Sentinel Lymph Node Biopsy · NCI — Breast Cancer Treatment (PDQ), Health Professional Version
5.Why does axillary treatment extent affect morbidity?
Axillary dissection disrupts more lymphatic channels and regional tissue than sentinel node biopsy, increasing risks such as arm lymphoedema, sensory disturbance and shoulder dysfunction. Regional irradiation can also contribute to morbidity, particularly when combined with extensive surgery. Treatment selection therefore balances regional disease control against functional harm. Recognizing an evidence-supported opportunity to reduce axillary surgery can preserve quality of life without sacrificing outcomes in the appropriate patient population.
Apply it
A patient eligible for omission of completion dissection worries that less surgery means inadequate treatment. Explain the relevant trial population, planned regional treatment and the reduction in arm morbidity associated with avoiding unnecessary axillary surgery.
Common pitfall: More extensive surgery is not automatically more effective. Conversely, morbidity concerns alone do not justify omitting treatment for clinically substantial or otherwise inadequately controlled nodal disease.
NCI — Breast Cancer Treatment (PDQ), Health Professional Version · JAMA — ACOSOG Z0011 randomized clinical trial: 10-year overall survival
6.How is nonmetastatic inflammatory breast cancer sequenced?
Inflammatory breast cancer is an aggressive clinical presentation characterized by rapid breast erythema, oedema and peau d'orange, reflecting tumour involvement of dermal lymphatics. For nonmetastatic disease, treatment generally begins with systemic therapy, followed by modified radical mastectomy and radiotherapy. Biomarker-directed treatments are incorporated when indicated. Initial systemic treatment addresses early dissemination risk and tests tumour responsiveness; surgery alone cannot adequately manage the diffuse breast and skin involvement.
Apply it
A patient develops rapid diffuse breast redness and oedema, with biopsy-confirmed invasive carcinoma and no distant metastases. Establish receptor status and initiate appropriate systemic therapy before definitive mastectomy and subsequent radiotherapy within the multidisciplinary plan.
Common pitfall: Treating this as an ordinary operable breast lump and proceeding directly to lumpectomy overlooks its diffuse clinical extent and the importance of systemic treatment first.
7.Why does oestrogen receptor status change treatment?
Oestrogen receptor expression identifies a biological pathway that can drive breast cancer growth and predicts potential benefit from endocrine therapy. It is predictive because it helps select a treatment, rather than merely describing baseline prognosis. Receptor results must be interpreted with tumour stage, menopausal status and other biological features. Strong endocrine sensitivity does not remove the need for appropriate local treatment or automatically establish that chemotherapy offers no additional benefit.
Apply it
Two patients have similarly sized breast tumours, but only one is oestrogen receptor positive. Explain why endocrine therapy is relevant to that patient's systemic plan while both still require stage-appropriate decisions about breast and axillary treatment.
Common pitfall: A favourable prognostic association does not make a biomarker purely prognostic. Treatment selection depends on whether the marker predicts benefit from a specific intervention.
NCI — Breast Cancer Treatment (PDQ), Health Professional Version
8.How should an equivocal HER2 result be resolved and interpreted?
Immunohistochemistry (IHC) assesses HER2 protein expression, whereas in situ hybridisation (ISH) assesses HER2 gene amplification. Under ASCO/CAP guidance, IHC 2+ is equivocal and requires reflex ISH; it does not establish conventional HER2 positivity. IHC 3+ establishes protein overexpression. For IHC 2+ cancers, the final integrated IHC/ISH interpretation determines whether the tumour is HER2 positive or negative for overexpression/amplification. Uncommon ISH patterns require the guideline's combined interpretation, including concurrent IHC review and recounting where specified.
Apply it
An invasive breast carcinoma is IHC 2+. Request reflex ISH. If the completed ASCO/CAP interpretation confirms amplification and HER2 positivity, the biomarker supports conventional HER2-directed treatment selection in the appropriate disease setting. If the integrated result is IHC 2+/ISH negative, classify it as negative for HER2 overexpression/amplification. Preserve the numerical IHC score because eligibility for some antibody–drug conjugate treatments uses expression results and additional clinical criteria separately.
Common pitfall: Do not equate IHC 2+ with a positive result, or confuse protein expression with gene amplification. Treatment-specific eligibility for an antibody–drug conjugate does not automatically reclassify an IHC 2+/ISH-negative cancer as conventionally HER2 positive. The 2023 ASCO/CAP update retained the testing algorithm and did not introduce a separate HER2-low interpretive category.
NCI — Breast Cancer Treatment (PDQ), Health Professional Version · HER2 Testing In Breast Cancer - 2023 Guideline Update - CAP
9.How should response to neoadjuvant breast therapy be interpreted?
Neoadjuvant systemic treatment can reduce breast and nodal tumour burden, facilitate surgery and reveal treatment sensitivity. Clinical or imaging disappearance does not establish pathological complete response, because microscopic viable disease can remain. Surgical planning must retain knowledge of the original tumour location and extent, while postoperative treatment decisions may depend on residual disease and tumour subtype. Response therefore changes the information available for planning without making baseline documentation or pathological assessment redundant.
Apply it
A previously palpable HER2-positive tumour becomes impalpable after systemic therapy. Use the documented tumour site and current imaging to plan surgery, then assess the resection specimen before declaring complete pathological response or determining subsequent systemic treatment.
Common pitfall: An apparently normal scan is not equivalent to a negative surgical specimen. Avoid assuming that clinical disappearance independently proves cure or routinely eliminates local treatment.
NCI — Breast Cancer Treatment (PDQ), Health Professional Version
Melanoma/Skin/Endocrinenot stated
10.How do Breslow thickness and ulceration stage melanoma?
Breslow thickness measures vertical invasion of the primary melanoma in millimetres and is a central determinant of its T category. Ulceration supplies additional adverse staging information within thickness groups. These features help estimate metastatic risk and guide discussion of excision margins and sentinel node staging. A lesion's surface diameter or colour variation may raise diagnostic suspicion, but neither substitutes for the histological depth and ulceration information needed for pathological staging.
Apply it
Two melanomas have the same measured thickness, but only one is ulcerated. Explain that their T subcategories and risk assessment can differ despite identical depth, then use both histological features in the regional staging discussion.
Common pitfall: Confusing horizontal lesion diameter with Breslow thickness can produce incorrect staging. Ulceration is a histological staging feature, not simply a patient's report of bleeding.
11.When should melanoma sentinel node biopsy be recommended, discussed or usually omitted?
ESMO recommends sentinel lymph node biopsy for clinically node-negative melanoma thicker than 1.0 mm. Discuss it for lesions 0.8–1.0 mm thick, with or without ulceration, and for ulcerated lesions below 0.8 mm. It is not routinely recommended for nonulcerated lesions below 0.8 mm. Exceptions warranting discussion in this latter group include 3 mitoses/mm², a positive deep biopsy margin or unreliable Breslow measurement. For selected T3b, T4a or T4b tumours qualifying for adjuvant therapy, omission can be discussed while explaining the staging and locoregional-control benefits that would be lost.
Apply it
A clinically node-negative patient with a 1.6 mm melanoma should generally be offered sentinel node biopsy with definitive excision. For a 0.9 mm lesion, discuss benefits and harms; for a reliably measured nonulcerated 0.6 mm lesion without exceptional features, routine sentinel biopsy is usually omitted.
Common pitfall: Exactly 1.0 mm belongs to the discussion group; the routine recommendation begins above 1.0 mm. A suspicious palpable node requires direct diagnostic evaluation rather than routine occult-node staging.
12.How does MEN2 alter the sequence of medullary thyroid cancer surgery?
Multiple endocrine neoplasia type 2 can combine medullary thyroid carcinoma with pheochromocytoma. Before thyroid surgery in this setting, assess for a catecholamine-secreting tumour using plasma free or urinary fractionated metanephrines, even if the patient has no current hypertensive symptoms. If a functional pheochromocytoma is present, establish appropriate adrenergic and volume preparation and treat it before the thyroid operation. Otherwise, anaesthesia or surgery can precipitate a catecholamine crisis. The inherited syndrome therefore changes the safety and sequence of thyroid cancer treatment.
Apply it
A patient with MEN2-associated medullary thyroid carcinoma is scheduled for thyroidectomy and reports episodic palpitations. Investigate pheochromocytoma before proceeding. If confirmed and functional, prepare and resect the catecholamine-secreting tumour first, then undertake thyroid cancer surgery.
Common pitfall: The thyroid malignancy's need for treatment does not justify bypassing pheochromocytoma assessment. Normal blood pressure between attacks cannot establish that proceeding directly to thyroid surgery is safe.
13.Which outcomes changed with completion dissection in MSLT-II?
MSLT-II compared immediate completion lymph node dissection with observation incorporating nodal ultrasonography after a positive melanoma sentinel node. Dissection improved regional nodal control and supplied additional prognostic information, but did not improve melanoma-specific survival. Lymphoedema was more frequent after dissection. The distinction between regional control and survival is essential: an intervention can reduce recurrence in one anatomical compartment without improving the endpoint most directly related to death from the cancer.
Apply it
A patient with a positive melanoma sentinel node asks whether immediate basin dissection improves survival. Explain the trial's melanoma-specific survival finding separately from its regional control benefit, and assess whether structured ultrasound surveillance is feasible for them.
Common pitfall: Describing the trial as showing no benefit of any kind is inaccurate. Regional control improved, while melanoma-specific survival did not; observation also required structured follow-up.
Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
14.How do checkpoint inhibitors restore antitumour immunity?
CTLA-4 limits CD28-mediated T-cell costimulation by competing with CD28 for CD80/CD86 on antigen-presenting cells. PD-1 engagement by PD-L1 or PD-L2 inhibits signalling in activated T cells, restraining their function in peripheral tissues, including tumours. Blocking these pathways can restore antitumour T-cell activity. Checkpoints also maintain immune tolerance, so blockade can weaken peripheral tolerance and permit inflammation against normal tissues. The therapeutic effect and immune-mediated toxicities therefore arise from altered immune regulation rather than direct cytotoxic injury to cancer cells.
Apply it
A patient receiving a PD-1 inhibitor for melanoma develops persistent diarrhoea. Consider immune-mediated colitis alongside infection and other causes. Explain that releasing inhibitory T-cell signalling can improve tumour control while allowing damaging inflammation in normal bowel.
Common pitfall: CTLA-4 and PD-1 are not interchangeable molecular targets: one limits CD28 costimulation through ligand competition, while the other transmits inhibitory signals after ligand engagement. Their blockade can also produce toxicities beyond the infusion period.
15.How does melanoma depth guide definitive excision?
The ESMO cutaneous melanoma guideline recommends full-depth wide local excision with clinical margins of 0.5 cm for melanoma in situ, 1 cm for invasive melanoma up to and including 2 mm thick, and 2 cm for lesions thicker than 2 mm. These are planned clinical margins, not required microscopic clearance measurements. Selected reduced margins or micrographic surgery may preserve function in acral or facial melanoma, including lentigo maligna melanoma. Coordinate sentinel node biopsy when indicated. Identify the guideline used because numerical recommendations can differ between systems.
Apply it
For a 1.6 mm invasive melanoma on the forearm, the ESMO framework supports a 1 cm clinical excision margin and discussion of concurrent sentinel node biopsy. A 2.4 mm lesion generally requires a 2 cm clinical margin under the same framework.
Common pitfall: A narrow diagnostic biopsy does not establish completion of definitive local treatment. Exactly 2 mm remains in ESMO's 1 cm group; anatomical modification requires a specific functional rationale and adequate local control.
16.Which biochemical tests support pheochromocytoma diagnosis?
Pheochromocytomas and sympathetic paragangliomas may release catecholamines, producing episodic headache, palpitations, sweating and hypertension. Plasma free metanephrines or urinary fractionated metanephrines provide biochemical evidence because catecholamine metabolism can remain detectable between symptomatic bursts. Interpret results in the context of collection conditions, medications and the degree of elevation. Establishing biochemical activity matters before invasive intervention, since tumour manipulation can provoke severe cardiovascular instability in an unprepared patient.
Apply it
A patient has an adrenal mass and episodic palpitations with marked blood pressure surges. Arrange appropriate metanephrine testing and endocrine assessment before considering biopsy or surgery, because an unsuspected catecholamine-secreting tumour changes procedural risk substantially.
Common pitfall: A normal blood pressure reading between attacks does not exclude secretion. An adrenal mass should not undergo casual needle biopsy before pheochromocytoma has been appropriately considered.
17.Why must alpha blockade precede beta blockade?
Catecholamine-secreting pheochromocytoma causes alpha-mediated vasoconstriction as well as cardiac stimulation. Preoperative alpha blockade reduces the vascular response; beta blockade may subsequently be added for persistent tachycardia when appropriate. Starting a beta blocker first can leave alpha-mediated vasoconstriction unopposed and precipitate severe hypertension. Preparation also addresses contracted circulating volume and perioperative haemodynamic risk. The sequence is a physiological safety principle, not merely a preference between equally interchangeable antihypertensive agents.
Apply it
A patient awaiting resection of a functional pheochromocytoma remains tachycardic. Confirm adequate alpha blockade and volume preparation before adding beta blockade, rather than treating the heart rate in isolation from the tumour's vascular effects.
Common pitfall: Suppressing tachycardia first may appear reassuring while worsening vascular resistance. The presence of hypertension does not make every antihypertensive sequence equally safe in catecholamine excess.
18.Why do hereditary features matter in pheochromocytoma?
Pheochromocytoma and paraganglioma can arise within inherited tumour predisposition syndromes. Young presentation, multifocal or bilateral tumours, paraganglioma and family history increase concern, although an apparently sporadic presentation does not exclude a germline cause. Genetic assessment can inform surveillance for additional tumours and identify relatives who may benefit from counselling and testing. The consequences extend beyond the immediate adrenal operation because inherited risk can persist after successful removal of the presenting lesion.
Apply it
A young adult has bilateral adrenal pheochromocytomas and a relative with an endocrine tumour. Incorporate genetic counselling and syndrome-directed assessment into treatment planning, then explain why postoperative follow-up and family assessment remain relevant after tumour removal.
Common pitfall: A negative family history is not proof of a nonhereditary tumour. Small families, unrecognized disease and newly arising variants can obscure an inherited predisposition.
Colorectal/Peritoneal Surface Malignanciesnot stated
19.How are colorectal T4a and T4b distinguished?
Colorectal T4a indicates penetration of the visceral peritoneal surface, whereas T4b indicates direct invasion of an adjacent organ or structure. Both describe local anatomical extension rather than nodal or distant spread. When a tumour is densely adherent to another organ at operation, separating the adhesion can breach malignant tissue if true invasion is present. Oncological planning therefore considers an en bloc resection when a complete, appropriate operation is achievable.
Apply it
A sigmoid tumour is inseparable from the bladder at surgery, with no distant disease identified. Plan an oncologically appropriate en bloc resection if feasible; final pathology determines whether the adhesion represented true adjacent-organ invasion and therefore T4b disease.
Common pitfall: Serosal penetration and invasion of a neighbouring organ are different T4 categories. An operative adhesion alone does not replace histological confirmation of malignant invasion.
NCI — Colon Cancer Treatment (PDQ), Health Professional Version
20.Why does lymph node assessment affect colon staging?
Regional lymph node metastasis changes colon cancer stage and usually strengthens the indication for adjuvant systemic treatment. Examination of at least 12 regional nodes is a commonly used adequacy benchmark for pathological staging. A small negative nodal sample may miss metastases and create stage migration, making an apparently node-negative cancer less securely classified. Node yield reflects surgery, pathological processing and patient factors; a low count is not itself proof that the tumour is node positive.
Apply it
A colectomy specimen contains a T3 tumour and only five negative nodes. Request review of nodal assessment and discuss the uncertainty of the node-negative classification when considering postoperative risk and treatment, rather than declaring occult positivity as established.
Common pitfall: Twelve examined nodes is an assessment benchmark, not the number required to be positive. A low negative yield raises uncertainty without automatically changing N category.
NCI — Colon Cancer Treatment (PDQ), Health Professional Version
21.How does mismatch repair status inform stage II colon treatment?
Stage II colon cancer has no established regional nodal metastasis, so adjuvant treatment decisions require a more selective assessment of recurrence risk and expected benefit than routine node-positive management. Deficient mismatch repair or microsatellite instability supplies important prognostic and treatment-predictive information. In particular, fluoropyrimidine monotherapy should not be assumed beneficial simply because the tumour is stage II. Interpret molecular findings alongside high-risk anatomical features, node assessment and the patient's overall fitness.
Apply it
A fit patient has completely resected stage II colon cancer with deficient mismatch repair and no other major adverse features. Explain why postoperative fluoropyrimidine monotherapy is not an automatic recommendation and distinguish this situation from established node-positive disease.
Common pitfall: A stage label alone does not establish identical chemotherapy benefit for every tumour. Avoid interpreting mismatch repair status without considering both treatment context and pathological risk.
NCI — Colon Cancer Treatment (PDQ), Health Professional Version
22.Why is pelvic MRI important in rectal cancer?
Pelvic MRI defines the local relationship between rectal tumour, mesorectum, mesorectal fascia and adjacent pelvic structures. This supports assessment of the likely circumferential resection margin and helps identify locally advanced disease requiring treatment beyond immediate surgery. Local staging answers a different question from distant staging with chest and abdominal imaging. A tumour's distance from the anal verge alone cannot establish the radial margin risk or the feasibility of an oncologically sound resection.
Apply it
A patient has a mid-rectal adenocarcinoma and no distant metastases on CT. Obtain pelvic MRI to assess local extension and the mesorectal fascia before deciding between immediate surgery and a neoadjuvant strategy within the multidisciplinary team.
Common pitfall: A negative distant staging CT does not establish favourable pelvic anatomy. Endoscopic tumour height and luminal appearance cannot reliably define the threatened circumferential margin.
NCI — Rectal Cancer Treatment (PDQ), Health Professional Version
23.How do mesorectal excision and circumferential margin assessment support local control?
Total mesorectal excision removes the rectum and mesorectal lymphovascular envelope along the appropriate anatomical plane. An intact specimen and adequate circumferential resection margin support local control. Under the CAP colorectal protocol, the radial margin is positive when tumour lies within 1 mm of the nonperitonealized resection surface, including exactly 1 mm. Pathological CRM assessment measures the resected specimen; pelvic MRI estimates the anticipated surgical margin before treatment or surgery. These assessments are related but are not interchangeable measurements.
Apply it
A rectal specimen has clear proximal and distal ends but only 0.7 mm between invasive tumour and the nonperitonealized radial surface. Record the CRM as involved under CAP criteria despite no tumour touching ink, and review its local-control implications with the multidisciplinary team.
Common pitfall: The breast no-ink standard cannot be transferred to rectal CRM assessment. Clear bowel ends do not compensate for an involved radial margin, and an MRI estimate does not replace postoperative pathological measurement.
NCI — Rectal Cancer Treatment (PDQ), Health Professional Version · ColoRectal_4.4.0.1.REL_CAPCP.pdf
24.How should rectal tumour regression change planning?
Neoadjuvant treatment can reduce rectal tumour burden and improve the prospects of local control or resection. Response assessment combines clinical examination, endoscopy and imaging; no single observation reliably excludes all residual viable cancer. A clinical complete response and a pathological complete response are different findings. Organ-preservation strategies require careful selection, explicit discussion of regrowth risk and structured surveillance, rather than an assumption that an initially impressive response makes subsequent assessment unnecessary.
Apply it
After neoadjuvant therapy, a low rectal tumour is no longer visibly protruding at endoscopy. Complete the planned clinical and imaging reassessment before considering surgery or an organ-preservation pathway, and explain the surveillance obligations of nonoperative management.
Common pitfall: Tumour shrinkage is not equivalent to pathological eradication. Avoid offering observation merely because symptoms improve or a single examination looks normal after treatment.
NCI — Rectal Cancer Treatment (PDQ), Health Professional Version
25.How does peritoneal disease distribution affect cytoreduction?
Assessment of peritoneal malignancy must describe both overall burden and anatomical distribution. Numerous removable deposits may pose a different problem from disease involving extensive small-bowel serosa or mesentery, where complete removal could leave inadequate viable bowel. Burden measures organize this assessment but do not replace judgment about resectability, biology and physiological reserve. The useful decision is whether an acceptable operation can achieve the intended cytoreduction, rather than whether visible disease is technically removable somewhere.
Apply it
Two patients have apparently similar peritoneal tumour burden, but one has extensive small-bowel mesenteric involvement. Explain why the expected completeness and functional consequences of cytoreduction may differ substantially, even before considering any intraperitoneal chemotherapy component of treatment.
Common pitfall: A burden score cannot independently establish operability or benefit. Ignoring small-bowel distribution can underestimate the risk of incomplete cytoreduction or unacceptable postoperative intestinal function.
The ESSO core curriculum committee update on surgical oncology
26.Why must cytoreduction and HIPEC be evaluated separately?
Cytoreductive surgery removes macroscopic peritoneal disease, whereas hyperthermic intraperitoneal chemotherapy adds a regional drug exposure intended to address residual microscopic disease. They are distinct treatment components. A comparison in which both groups receive cytoreduction estimates the added effect of the tested HIPEC regimen, not the entire value of surgery. Interpretation must retain the tumour type, selection criteria, chemotherapy protocol and endpoints studied; evidence for one combination does not establish a universal class effect.
Apply it
A trial gives complete cytoreduction to both groups and adds HIPEC to only one. Frame its question as the incremental benefit and harm of that HIPEC protocol, rather than a direct comparison of surgery against no surgery.
Common pitfall: Neither a favourable surgical series nor an unsuccessful added-treatment trial isolates every component's effect. Avoid transferring results across different primaries or intraperitoneal regimens without justification.
The ESSO core curriculum committee update on surgical oncology · ICH E9 — Statistical Principles for Clinical Trials
27.How should an uncertain HIPEC trial result be interpreted?
A nonsignificant superiority result does not prove that treatments are equivalent. Examine the treatment effect estimate, confidence interval, prespecified endpoint and trial design to determine which clinically important benefits or harms remain compatible with the data. In peritoneal malignancy, also inspect whether eligibility required complete cytoreduction and how complications were assessed. Exploratory subgroups can generate hypotheses, but an isolated favourable subgroup should not override the primary randomized comparison without appropriate supporting evidence.
Apply it
A hypothetical added-HIPEC trial reports a survival hazard ratio of 0.95 with a 95% confidence interval of 0.70–1.29. Explain that superiority was not demonstrated and that the interval still includes potentially important benefit and harm.
Common pitfall: Calling treatments equivalent because a P value exceeds 0.05 confuses failure to show superiority with a properly designed equivalence or noninferiority conclusion.
ICH E9 — Statistical Principles for Clinical Trials · The ESSO core curriculum committee update on surgical oncology
Upper GInot stated
28.How does oesophageal T1 depth affect treatment selection?
Oesophageal T1 disease is subdivided by depth: T1a involves the lamina propria or muscularis mucosae, while T1b reaches the submucosa. Submucosal invasion increases concern for lymphatic spread, so a small surface lesion is not necessarily suitable for local treatment alone. Endoscopic resection can provide detailed pathological staging in selected superficial disease. Depth, differentiation, lymphovascular invasion and completeness of excision must be integrated when deciding whether endoscopic treatment is sufficient.
Apply it
An apparently superficial oesophageal lesion is removed endoscopically, but pathology shows submucosal invasion. Reassess nodal risk and definitive treatment options rather than assuming the visually small lesion was adequately managed by local excision alone in this patient.
Common pitfall: Surface size and T category are not interchangeable. A technically complete endoscopic excision does not by itself establish negligible regional lymph node risk.
NCI — Esophageal Cancer Treatment (PDQ), Health Professional Version
29.What does endoscopic ultrasound add to oesophageal staging?
Endoscopic ultrasound examines oesophageal wall layers and nearby lymph nodes, helping assess local tumour depth and regional spread. Its role complements rather than replaces distant staging. Selected suspicious nodes can undergo needle assessment when the result would change management and sampling is appropriate. A tumour that cannot be traversed or changes after treatment may limit accuracy. Treatment decisions therefore integrate endoscopic, pathological and cross-sectional information instead of assigning every staging task to one modality.
Apply it
A patient has biopsy-confirmed oesophageal carcinoma without distant metastases on initial imaging. Use endoscopic ultrasound, when feasible, to refine local depth and nodal assessment before deciding whether the disease fits a superficial or more advanced treatment pathway.
Common pitfall: A favourable local ultrasound result does not exclude distant metastases. Enlarged regional nodes are suspicious findings, but size alone does not provide histological confirmation of involvement.
NCI — Esophageal Cancer Treatment (PDQ), Health Professional Version
30.When can distal gastric cancer receive subtotal gastrectomy?
Subtotal gastrectomy can be appropriate for a distal gastric cancer when an adequate oncological resection, including clear margins and appropriate regional lymphadenectomy, is achievable. Total gastrectomy is selected when tumour location or extent prevents that clearance while preserving part of the stomach. Removing the entire stomach is not intrinsically superior for every distal lesion. Extent of resection should follow the tumour's anatomy and growth pattern while accounting for postoperative nutritional and functional consequences.
Apply it
A distal gastric adenocarcinoma has no proximal extension on assessment, and adequate clearance is feasible with subtotal resection. Discuss subtotal gastrectomy with appropriate lymphadenectomy rather than recommending total gastrectomy solely because the diagnosis is gastric cancer.
Common pitfall: Organ preservation is appropriate only with adequate clearance. Conversely, choosing the largest possible resection without an anatomical indication adds functional cost without establishing an oncological advantage.
NCI — Gastric Cancer Treatment (PDQ), Health Professional Version
31.How do D1, D1+ and D2 lymphadenectomy differ for distal gastrectomy?
In the Japanese Gastric Cancer Association sixth-edition framework, distal-gastrectomy D1 removes stations 1, 3, 4sb, 4d, 5, 6 and 7. D1+ adds stations 8a and 9; D2 adds stations 8a, 9, 11p and 12a to D1. D2 therefore extends clearance to additional nodal groups along major regional arteries. These station sets are operation-specific: the distal-gastrectomy definition must not be transferred unchanged to total gastrectomy. For potentially curable cT2–T4 or clinically node-positive disease, D2 is the usual indicated dissection in this framework.
Apply it
A patient with cT2N0 distal gastric adenocarcinoma requiring distal gastrectomy should receive D2 clearance despite the absence of enlarged nodes. For cT1N0 disease requiring surgery, D1 is indicated for cT1a lesions unsuitable for endoscopic resection and differentiated cT1b lesions measuring 1.5 cm or less. Other cT1N0 tumours generally receive D1+. If nodal involvement or deeper invasion cannot reasonably be excluded, the framework favours D2.
Common pitfall: A high node count cannot compensate for omission of a required station, and selective removal of enlarged nodes is not D2. Conversely, D2 does not itself require routine splenectomy or pancreatic resection. Name the gastrectomy and guideline framework before describing the dissection, because anatomical definitions vary with the operation.
NCI — Gastric Cancer Treatment (PDQ), Health Professional Version · A 手術｜Ⅱ章 治療法｜胃癌治療ガイドライン 第6版｜日本胃癌学会
32.Why is splenectomy avoided routinely during gastrectomy?
Routine splenectomy adds operative and infectious morbidity and is not required merely to make a gastric cancer operation more radical. Preservation is appropriate when adequate tumour clearance and the indicated nodal dissection can be achieved without removing the spleen. Direct tumour invasion creates a different situation in which en bloc organ removal may be needed for clearance. The key distinction is a specific oncological indication versus prophylactic extension of an otherwise adequate operation.
Apply it
During planning for a proximal gastric cancer, imaging shows no splenic invasion. Assess the required resection and lymphadenectomy without automatically adding splenectomy, and explain that preserving an uninvolved spleen can reduce avoidable morbidity in an otherwise adequate operation.
Common pitfall: Avoiding routine splenectomy does not mean preserving an organ directly invaded by resectable tumour at the expense of clearance. The indication must be individualized.
NCI — Gastric Cancer Treatment (PDQ), Health Professional Version
33.Why is perioperative therapy considered in gastric cancer?
Resectable gastric cancer can already carry occult systemic disease, so local removal alone may not adequately address recurrence risk. Perioperative systemic treatment integrates chemotherapy with surgery for appropriate patients, treating potential micrometastases and sometimes reducing tumour burden before resection. Selection depends on stage, fitness and the treatment strategy being used. A radiological response does not establish that surgery or pathological assessment is unnecessary, and a regimen's evidence must be matched to the population studied.
Apply it
A fit patient has locally advanced, nonmetastatic gastric adenocarcinoma. Discuss a coordinated perioperative systemic treatment and surgical pathway rather than assuming anatomical resectability makes immediate surgery alone the best complete oncological strategy for this patient.
Common pitfall: Resectable does not mean biologically confined to the stomach. Conversely, a patient unable to tolerate systemic treatment needs an individualized plan rather than automatic application of a trial regimen.
NCI — Gastric Cancer Treatment (PDQ), Health Professional Version
34.Which gastric cancers warrant staging laparoscopy, and how can its findings change treatment intent?
Staging laparoscopy detects peritoneal dissemination that cross-sectional imaging may miss. The [2025 European consensus](https://pmc.ncbi.nlm.nih.gov/articles/PMC12412212/) identifies cT3–4 disease, clinically positive regional nodes, poorly cohesive histology and radiological suspicion of peritoneal metastases as selection cues. The procedure includes systematic peritoneal inspection, biopsy of suspicious lesions and cytological sampling. Collect ascites for cytology when sufficient fluid is present; otherwise perform peritoneal lavage. Cytology is a standard component because malignant cells may be present without visible implants. Confirmed peritoneal dissemination changes staging and can redirect a planned curative gastrectomy toward systemic treatment.
Apply it
A patient has cT3N-positive gastric adenocarcinoma with poorly cohesive histology and no definite metastases on CT. These findings support staging laparoscopy before the planned curative treatment pathway proceeds. Even if inspection reveals no implants and there is no ascites, obtain lavage cytology. A visually negative examination alone does not complete peritoneal staging.
Common pitfall: Do not require ascites or obvious implants before obtaining cytology. Negative CT imaging does not exclude microscopic peritoneal disease, and technical feasibility of gastrectomy does not establish that resection offers curative benefit.
NCI — Gastric Cancer Treatment (PDQ), Health Professional Version
35.How should oesophageal obstruction influence supportive planning?
Oesophageal cancer can cause dysphagia, dehydration and malnutrition that undermine performance status and the ability to receive treatment. Nutritional assessment and symptom relief should accompany oncological staging, with the method chosen according to treatment intent and expected duration of need. Endoscopic palliation may provide rapid swallowing relief in selected advanced disease, while patients entering potentially curative therapy require a strategy compatible with that plan. Technical relief of obstruction does not itself control systemic cancer.
Apply it
A patient with advanced oesophageal cancer can swallow only liquids and has lost substantial weight. Assess hydration, nutrition and goals of care while considering a proportionate intervention for dysphagia alongside systemic or other symptom-directed treatment.
Common pitfall: Restoring the lumen is not the same as treating the cancer comprehensively. Avoid selecting a palliative device without considering treatment intent, complications and the patient's priorities.
NCI — Esophageal Cancer Treatment (PDQ), Health Professional Version · NCI — Palliative Care in Cancer
Hepato/Pancreatico/Biliarynot stated
36.When can imaging establish hepatocellular carcinoma?
In an appropriate high-risk population, characteristic multiphasic imaging can establish hepatocellular carcinoma without routine biopsy. Arterial phase hyperenhancement followed by washout on later phases reflects the altered vascular supply of many HCCs. Diagnostic interpretation depends on lesion characteristics, size, imaging quality and the underlying risk setting. The same enhancement pattern in a person without an appropriate high-risk background should not automatically receive identical diagnostic certainty; indeterminate lesions require further evaluation.
Apply it
A patient with cirrhosis has a new liver lesion showing characteristic arterial enhancement and later washout on diagnostic multiphasic imaging. Apply the appropriate imaging diagnostic framework before deciding whether tissue sampling is necessary for this patient's management.
Common pitfall: A single arterial image is insufficient to demonstrate washout. Avoid extending noninvasive HCC diagnostic rules indiscriminately to every incidental liver lesion in a normal liver.
NCI — Primary Liver Cancer Treatment (PDQ), Health Professional Version · AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
37.How does suspected cholangiocarcinoma location determine diagnostic sampling?
Cholangiocarcinoma can present as a biliary stricture without a discrete mass. MRI/MRCP maps the obstruction and ductal extent; diagnosis also requires assessment for benign mimics. ESGE recommends combined EUS-guided and ERCP-based tissue acquisition for jaundiced patients with a distal extrahepatic stricture and no pancreatic mass. For perihilar strictures, combine brushing cytology with fluoroscopy-guided biopsies when feasible. After insufficient ERCP sampling, consider EUS-guided acquisition when curative resection is infeasible and/or accessible extraluminal disease is present. Indeterminate strictures may require additional cholangioscopy-guided biopsies.
Apply it
A jaundiced patient has a perihilar stricture suspicious for cholangiocarcinoma. Map the ducts with MRI/MRCP, assess resectability, and plan ERCP brushings plus fluoroscopic biopsies. Select any subsequent EUS sampling according to curative feasibility and accessible extraluminal disease.
Common pitfall: A negative brushing does not reliably exclude a desmoplastic biliary malignancy. Distal and perihilar strictures require different sampling strategies, and neither CA19-9 nor an isolated IgG4 elevation establishes the diagnosis.
38.How does liver reserve constrain HCC resection?
HCC resection must remove the tumour while leaving enough functioning liver to avoid postoperative liver failure. In cirrhosis, portal hypertension, synthetic dysfunction and limited functional reserve can make an anatomically feasible operation unsafe. Assessment therefore integrates tumour extent, liver function, clinically significant portal hypertension and the future liver remnant. A small tumour does not automatically imply low operative risk, because the diseased background liver may determine whether resection, transplantation or another treatment is most appropriate.
Apply it
A patient has a solitary small HCC but ascites and evidence of portal hypertension. Do not select resection from tumour size alone; assess hepatic reserve and alternative strategies, including transplant suitability where appropriate to the complete clinical picture.
Common pitfall: An adequate-looking liver volume may still function poorly in cirrhosis. Normal tumour markers and technical resectability do not establish safety of hepatic resection.
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
39.Which HCC features fit conventional Milan transplant criteria?
Conventional Milan criteria describe a single HCC no larger than 5 cm, or up to three tumours each no larger than 3 cm, without macrovascular invasion or extrahepatic spread. They help identify a tumour burden associated with acceptable transplant outcomes. Transplantation treats both the cancer and the underlying diseased liver, unlike local tumour removal alone. Meeting tumour criteria does not independently guarantee listing; physiological suitability, allocation rules and other transplant assessments still apply.
Apply it
A cirrhotic patient has two HCCs measuring 2.4 cm and 2.8 cm, without vascular invasion or extrahepatic disease. Recognize that the tumour burden fits conventional Milan criteria and proceed to a complete transplant suitability assessment.
Common pitfall: Do not add the diameters together and compare the sum with the solitary-tumour limit. Tumour criteria are also distinct from jurisdiction-specific listing and allocation decisions.
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
40.How can portal vein embolization improve resection feasibility?
Portal vein embolization redirects portal flow away from the liver planned for resection toward the future liver remnant, encouraging remnant hypertrophy. It may permit a major hepatectomy when the anticipated remnant would otherwise be inadequate. The response must be reassessed before surgery because growth, function and tumour progression all affect feasibility. Volume thresholds are not interchangeable across normal liver, chemotherapy-injured liver and cirrhosis; more damaged parenchyma generally requires greater functional reserve.
Apply it
A patient needs a major right-sided liver resection, but the predicted left-sided remnant is inadequate. Consider portal vein embolization and reassessment of remnant growth and function before committing to an operation that risks postoperative liver failure.
Common pitfall: Embolization prepares the remnant; it does not itself establish tumour clearance or guarantee safe hepatectomy. An increase in size must be interpreted alongside functional capacity.
AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
41.How does pancreatic tumour location determine the operation?
For resectable pancreatic cancer, tumour location determines which anatomical resection can achieve clearance. Head lesions generally require pancreaticoduodenectomy, whereas body or tail lesions generally require distal pancreatectomy. The operation must account for adjacent structures, regional nodes and margins, rather than merely shelling out the mass. Choosing the correct anatomical operation does not establish that surgery is indicated: distant staging, vascular involvement, patient fitness and the overall systemic treatment strategy remain separate decisions.
Apply it
A patient has a resectable pancreatic tail adenocarcinoma without distant disease. Discuss distal pancreatectomy within the oncological plan rather than pancreaticoduodenectomy, while separately assessing regional anatomy, operative fitness and the need for systemic treatment around surgery.
Common pitfall: The Whipple operation is not the universal operation for pancreatic cancer. Conversely, a location-appropriate resection is not useful curative treatment when metastatic disease changes the intent.
NCI — Pancreatic Cancer Treatment (PDQ), Health Professional Version
42.Which vascular findings distinguish resectable, borderline resectable and locally advanced pancreatic head cancer at diagnosis?
Using NCCN Pancreatic Adenocarcinoma v2.2025, selected anatomical criteria for nonmetastatic pancreatic head/uncinate cancer distinguish arterial contact from venous reconstructibility. Resectable disease has no tumour contact with the superior mesenteric artery (SMA), coeliac axis or common hepatic artery, and no superior mesenteric vein/portal vein (SMV/PV) contact or contact of 180° or less without venous contour irregularity. Borderline resectable findings include SMA contact of 180° or less, or common hepatic artery contact without extension to the coeliac axis or hepatic bifurcation when safe complete resection and reconstruction are feasible. SMV/PV contact exceeding 180°, or contact of 180° or less with contour irregularity or thrombosis, is borderline when suitable proximal and distal vessels permit safe resection and reconstruction. SMA or coeliac axis contact exceeding 180° supports locally advanced classification. Complete SMV/PV occlusion that is not currently amenable to resection and primary reconstruction also supports locally advanced classification. These categories describe anatomy at diagnosis; locally advanced classification does not establish definitive unresectability.
Apply it
A 2.5-cm pancreatic head adenocarcinoma has 120° SMA contact and a short SMV occlusion with suitable reconstructible segments above and below, without metastases. Both findings support borderline resectable classification despite the small tumour diameter. Obtain tissue confirmation before neoadjuvant therapy, then restage and reassess surgical feasibility. By comparison, 210° SMA contact supports locally advanced classification at diagnosis. After treatment, surgical assessment must integrate disease progression, treatment response, patient fitness and the feasibility of complete resection and any necessary vascular reconstruction; the original category alone does not permanently determine surgical eligibility.
Common pitfall: Do not treat every venous occlusion as locally advanced: suitable vessels permitting reconstruction distinguish borderline venous involvement from more extensive occlusion. Conversely, tumour size alone cannot establish resectability when major vessels are involved. Keep classification at diagnosis separate from assessment after neoadjuvant treatment, and avoid translating 'locally advanced' into 'never operable.' Metastatic disease and physiological fitness independently affect treatment selection. Apply these selected head/uncinate criteria to the stated tumour location rather than transferring them indiscriminately to body/tail cancers.
NCI — Pancreatic Cancer Treatment (PDQ), Health Professional Version · 7.1d%20NCCN%202.2025%20pancreatic.pdf
43.How do metastatic status and vascular anatomy guide pancreatic adenocarcinoma treatment intent and subsequent surgical reassessment?
Assess distant metastases separately from local vascular anatomy using pancreatic-protocol imaging. Multiple confirmed liver metastases generally favour systemic treatment and supportive care rather than primary pancreatic resection as a curative strategy. In nonmetastatic disease, NCCN Pancreatic Adenocarcinoma v2.2025 distinguishes anatomical classification at diagnosis from eligibility for surgery after treatment. For example, complete superior mesenteric vein/portal vein occlusion that currently prevents resection and primary reconstruction is a locally advanced venous pattern. The guideline explicitly states that locally advanced classification does not imply definitive unresectability. Selected patients may therefore undergo specialist reassessment after systemic treatment.
Apply it
Contrast two patients with pancreatic head cancer. Multiple confirmed liver metastases redirect the first patient's treatment toward systemic therapy, pain relief and biliary decompression when indicated. The second patient has nonmetastatic disease initially classified as locally advanced because of vascular involvement. After systemic treatment, a significant CA19-9 decline and clinical improvement support reassessment at a high-volume multidisciplinary centre. Restaging must evaluate metastatic progression, fitness and the feasibility of complete resection, including any required vascular reconstruction; favourable response does not automatically establish operability.
Common pitfall: Do not equate the initial locally advanced category with a permanent prohibition on surgery, or treat all venous contact as equivalent to complete occlusion preventing reconstruction. Conversely, local technical removability does not overcome disseminated disease. Interpret CA19-9 after addressing biliary obstruction, which can elevate the marker independently of tumour progression.
NCI — Pancreatic Cancer Treatment (PDQ), Health Professional Version · 7.1d%20NCCN%202.2025%20pancreatic.pdf
44.How should biliary obstruction affect CA19-9 interpretation?
CA19-9 is a sialylated Lewis blood-group antigen whose production depends on Lewis-antigen biology; some patients produce little or none, limiting the reassurance offered by a normal result. Cholestasis and cholangitis can elevate CA19-9 in benign as well as malignant disease, reducing specificity during obstructive jaundice. Interpret the marker with imaging, pathology and the clinical state, and reassess after relief of obstruction when appropriate. Neither an elevated obstructed value nor a subsequent fall independently establishes histology, metastatic stage or anatomical resectability.
Apply it
A patient with a pancreatic head mass and marked obstructive jaundice has high CA19-9. Establish vascular anatomy and distant disease by staging investigations, obtain tissue when indicated, and interpret any marker change after decompression as complementary information rather than a replacement for staging.
Common pitfall: A high CA19-9 during cholestasis does not independently establish metastatic cancer. A normal result cannot exclude malignancy, particularly when Lewis-antigen biology limits marker production.
NCI — Pancreatic Cancer Treatment (PDQ), Health Professional Version · 2024_a-2481-7048.pdf
Sarcomanot stated
45.How should a suspected soft-tissue sarcoma be biopsied?
Biopsy of a suspected sarcoma should follow appropriate imaging and be planned with the team responsible for definitive treatment. A core needle approach commonly provides tissue for histological and molecular assessment while limiting contamination. The tract should be positioned so that it can be managed within the eventual resection, avoiding unnecessary tissue compartments and neurovascular structures. An unplanned excision can obscure the original extent, leave residual tumour and enlarge the field requiring subsequent treatment.
Apply it
A patient has a deep enlarging thigh mass with imaging suspicious for sarcoma. Coordinate a planned image-guided core biopsy whose tract fits the definitive surgical approach, rather than removing the mass through a convenient unrelated incision.
Common pitfall: A small skin incision does not make an unplanned excision oncologically harmless. Biopsy route and tissue contamination can materially affect the later operation and functional outcome.
NCI — Soft Tissue Sarcoma Treatment (PDQ), Health Professional Version
46.How do sarcoma grade, anatomical TNM extent and prognostic stage grouping relate?
Histological grade describes aggressiveness, using differentiation, mitotic activity and necrosis in applicable grading systems. Anatomical TNM describes the primary tumour's extent, regional nodes and distant metastases. AJCC prognostic stage groups for relevant adult soft-tissue sarcomas combine histological grade with TNM and depend on the primary site. Grade therefore differs from anatomical extent but can contribute directly to the final stage group. Histological subtype matters because grading and staging schemes do not apply identically to every sarcoma.
Apply it
Two extremity sarcomas have the same size, N category and M category but different histological grades. Recognize that they share anatomical TNM extent yet may have different AJCC prognostic stage groups and recurrence risks; use the correct site-specific staging table.
Common pitfall: Do not claim that sarcoma stage grouping is purely anatomical or that grade and stage are unrelated. Large size alone does not define grade, and a clear margin does not eliminate distant recurrence risk.
NCI — Soft Tissue Sarcoma Treatment (PDQ), Health Professional Version
47.Why are planned margins central to sarcoma surgery?
Soft-tissue sarcoma surgery aims for complete removal with an appropriate margin while preserving useful function when feasible. The apparent capsule around a mass may be a compressed tissue boundary rather than a reliable barrier to microscopic extension. Enucleation can therefore leave disease despite easy separation from surrounding tissues. Margin planning integrates anatomy, histological subtype, prior biopsy and the possible role of radiotherapy; limb preservation is judged by both cancer control and the function of the remaining limb.
Apply it
A thigh sarcoma abuts a major neurovascular bundle. Plan margins and any complementary treatment through the specialist team, weighing complete clearance and realistic postoperative function rather than choosing simple shelling-out because the mass feels well circumscribed.
Common pitfall: A smooth surface does not establish a safe dissection plane. Conversely, the widest conceivable operation is not automatically preferable when a planned functional, oncologically adequate approach exists.
NCI — Soft Tissue Sarcoma Treatment (PDQ), Health Professional Version
48.Which inherited clues matter in sarcoma assessment?
Some sarcomas arise in inherited cancer predisposition settings, including TP53-related Li-Fraumeni syndrome and neurofibromatosis type 1. Young age, multiple primary cancers, characteristic personal findings and a suggestive family history can prompt genetic assessment. Recognizing predisposition may influence surveillance, counselling and aspects of treatment planning. The relevant clue is a coherent pattern of tumours or clinical features, rather than assuming that every sarcoma is inherited or that absent family history excludes a germline disorder.
Apply it
A young patient with sarcoma has previously had another early-onset cancer and several relatives developed cancer unusually young. Incorporate genetic counselling into assessment because the pattern may affect the patient's continuing care and relatives' risk assessment.
Common pitfall: A hereditary association does not establish the diagnosis of a syndrome from one tumour alone. Avoid reassuring solely from an incomplete or apparently negative family history.
NCI — Soft Tissue Sarcoma Treatment (PDQ), Health Professional Version
49.How does localized GIST surgery differ from adenocarcinoma surgery?
Localized gastrointestinal stromal tumour is generally treated by complete resection while preserving the tumour's integrity. Extensive organ sacrifice and routine lymphadenectomy are usually unnecessary because typical GIST spreads differently from common gastrointestinal adenocarcinomas and rarely involves regional nodes. The operation should avoid rupture and achieve appropriate clearance without demanding a carcinoma-style anatomical resection in every case. Unusual subtypes or suspicious nodes require individualized assessment rather than an absolute assumption that nodal disease can never occur.
Apply it
A localized gastric GIST is suitable for an intact limited resection. Plan removal without tumour rupture and without automatically adding a formal gastric-cancer lymphadenectomy, while assessing whether the proposed operation preserves function and achieves adequate clearance.
Common pitfall: Applying an adenocarcinoma operation by default can add avoidable morbidity. Limited resection still requires oncological discipline; it does not justify cutting through or rupturing the tumour.
50.Why does GIST genotype matter before imatinib?
GIST sensitivity to kinase inhibition depends on its molecular driver, so pathological diagnosis alone does not establish imatinib responsiveness. KIT and PDGFRA variants differ in drug sensitivity; PDGFRA D842V is a key example of primary imatinib resistance. Molecular testing is particularly important when systemic treatment is being considered before surgery or as adjuvant therapy. Selecting treatment from genotype prevents ineffective exposure and helps avoid delaying a potentially useful surgical or alternative systemic strategy.
Apply it
A patient is being considered for preoperative imatinib to reduce the morbidity of GIST resection. Obtain molecular characterization first; identification of PDGFRA D842V would undermine an imatinib-based shrinkage plan and require a different specialist strategy.
Common pitfall: KIT immunostaining identifies a diagnostic feature, not the precise mutation or guaranteed drug sensitivity. Do not equate all PDGFRA mutations with the same treatment response.
51.Which features determine GIST recurrence risk?
GIST recurrence risk depends on tumour size, mitotic activity, anatomical site and rupture, rather than size alone. Gastric and nongastric primaries can have different risks at comparable size and mitotic rate. Rupture is particularly adverse because it can disseminate tumour cells into the peritoneal cavity. Risk assessment informs surveillance and adjuvant treatment discussions, while molecular sensitivity determines whether a proposed targeted drug is biologically appropriate for that particular tumour.
Apply it
Two GISTs have the same diameter, but one is gastric with low mitotic activity and the other is small-bowel with a high mitotic count. Explain why their recurrence risks and postoperative treatment discussions should not be identical.
Common pitfall: A clear microscopic margin does not erase the consequences of rupture. Risk classification and drug sensitivity answer separate questions and both matter when considering adjuvant imatinib.
52.When can neoadjuvant imatinib improve a GIST operation?
Preoperative imatinib may be considered for a molecularly sensitive GIST when shrinkage could make resection safer, preserve an organ or reduce rupture risk. Treatment requires a tissue diagnosis and molecular assessment before relying on drug response. Early response evaluation checks that the strategy is working, and surgery must remain actively planned. An unsuccessful drug trial can permit progression, so neoadjuvant treatment is a deliberate surgical strategy rather than an indefinite postponement of local management.
Apply it
A sensitive rectal GIST would initially require a highly morbid operation. Discuss preoperative imatinib to improve the prospects of functional preservation, with planned response assessments and reassessment of surgical timing rather than an open-ended course of treatment.
Common pitfall: Neoadjuvant treatment is inappropriate if sensitivity is merely assumed or progression goes unrecognized. Shrinkage also does not justify abandoning precautions against rupture during the eventual operation.
General Oncologynot stated
53.Why do randomization and allocation concealment serve different roles?
Randomization uses a chance mechanism to allocate participants, helping balance known and unknown prognostic factors across treatment groups. Allocation concealment prevents recruiters from predicting the next assignment before a participant enters the trial, protecting against selective enrolment. A genuinely random sequence can still be undermined if the next treatment is visible. Neither mechanism guarantees identical baseline characteristics in every realized sample, and both differ from masking treatment after the allocation has occurred.
Apply it
A surgical trial uses a computer-generated sequence, but recruiters can view the next assignment before enrolment. Identify a selection-bias vulnerability despite the random sequence, and explain why concealed allocation is needed to protect the comparison.
Common pitfall: Calling a sequence random does not prove its implementation was secure. Baseline imbalance alone also does not establish fraud or invalidate an otherwise properly randomized trial.
54.How can blinding improve a surgical trial?
Blinding reduces bias arising when knowledge of treatment affects care, reporting, endpoint assessment or analysis. Surgeons often cannot be blinded to the operation performed, but independent assessors may still be masked for imaging, pathology or functional outcomes. The relevant question is who knew the allocation and how that knowledge could influence the endpoint. Objective mortality outcomes and subjective symptom scores have different vulnerabilities, so an open-label design requires endpoint-specific appraisal rather than automatic dismissal.
Apply it
A trial compares two visible surgical techniques and measures postoperative functional scores. Assess whether independent outcome assessors were blinded and whether follow-up was standardized, even though the operating surgeons necessarily knew which procedure they performed.
Common pitfall: Impossible surgeon blinding does not make every form of masking impossible. Conversely, the label double-blind is uninformative unless the report identifies who was actually blinded.
55.What makes a noninferiority conclusion valid?
A noninferiority trial asks whether a new strategy loses no more than a prespecified acceptable amount of efficacy compared with an active control. The margin requires clinical and statistical justification before results are known. Interpretation compares the confidence interval with that margin, using the trial's specified effect direction. Poor adherence or crossover can obscure differences, so analyses and trial conduct need careful scrutiny. A nonsignificant superiority test does not independently establish noninferiority.
Apply it
A less extensive operation reduces morbidity but might slightly increase recurrence. Assess whether the trial prespecified an acceptable recurrence margin and whether its confidence interval excludes greater loss before concluding that the surgical reduction is noninferior.
Common pitfall: Choosing a generous margin after seeing the data defeats the design. Failure to detect a difference is not the same as excluding a clinically unacceptable loss.
56.How are absolute benefit and number needed to treat calculated?
Absolute risk reduction is the control event risk minus the treatment event risk over a specified follow-up period. Number needed to treat is its reciprocal when risks are expressed as proportions. If recurrence falls from 20% to 15%, the absolute reduction is 0.05 and the NNT is 20 over that period. Relative reduction answers a different question and can appear impressive despite a small absolute benefit when baseline risk is low.
Apply it
A hypothetical trial reports three-year recurrence of 30% with standard care and 24% with added treatment. Calculate a six-percentage-point absolute reduction and an NNT of about 17 over three years, then weigh this benefit against toxicity.
Common pitfall: Do not invert a percentage written as a whole number or confuse relative reduction with absolute reduction. NNT also needs an endpoint and time horizon.
57.Why is a hazard ratio not an absolute risk reduction?
A hazard ratio compares event rates over time among participants still at risk; it does not directly report the difference in cumulative event probabilities at a particular date. A hazard ratio below one may favour treatment, but absolute benefit also depends on baseline risk and follow-up. Inspect confidence intervals, survival curves and the appropriateness of the model, especially if hazards vary over time. Statistical significance alone cannot establish that the magnitude is clinically important.
Apply it
A cancer trial reports a hazard ratio of 0.80. Before telling a patient that treatment prevents 20 events per 100 people, inspect the actual survival probabilities at a relevant time and calculate their absolute difference.
Common pitfall: A 20% lower estimated hazard is not a 20-percentage-point survival improvement. Avoid translating a relative time-to-event measure directly into an individual absolute probability.
58.How does a treatment-policy estimand handle switching?
An estimand specifies the treatment effect a trial aims to estimate, including how intercurrent events such as treatment switching are handled. A treatment-policy strategy assesses outcomes regardless of such switching, addressing the effect of assignment to the treatment strategy in that trial context. It does not automatically estimate the biological effect of uninterrupted exposure. Simply censoring at switching changes the question and can introduce bias when switching relates to prognosis or response.
Apply it
In a randomized oncology trial, some control patients later receive the experimental drug. Explain whether the stated treatment-policy analysis includes their subsequent survival and distinguish that assignment effect from a hypothetical effect if switching had never occurred.
Common pitfall: Preserving randomized groups does not fully describe every estimand choice. Missing outcomes still require an appropriate plan; treatment policy does not make absent data disappear.
59.When should palliative care accompany cancer treatment?
Palliative care addresses physical symptoms, psychological distress, social needs and spiritual concerns associated with serious illness. It can be integrated with active anticancer treatment and is not restricted to the final days of life. Early involvement can support symptom control, communication and caregiver needs while treatment continues. The clinical trigger is unmet need and serious illness burden, rather than a requirement that surgery, radiotherapy or systemic treatment has first been abandoned.
Apply it
A patient receiving systemic treatment has pain, poor sleep and intense family distress. Add palliative care alongside oncology treatment, explaining that symptom and communication support can proceed concurrently with efforts to control the cancer and prolong life.
Common pitfall: Equating palliative care with imminent death can delay useful support. Continuing anticancer treatment does not mean symptoms, caregiver burden or goals-of-care discussions should wait.
60.How should a palliative procedure be judged?
A palliative procedure is judged by whether it is likely to relieve a meaningful problem within the patient's available time and with an acceptable burden. Expected symptom benefit, recovery time, complications, alternatives and the patient's priorities matter more than technical feasibility alone. A bypass, stent or limited operation may be useful without curing the cancer, but a major intervention can consume much of a frail patient's remaining life without delivering the desired function.
Apply it
A frail patient with advanced cancer has obstruction and hopes to return home quickly. Compare expected relief, recovery and complications of procedural and nonprocedural options, then choose a plan linked explicitly to that goal and likely clinical course.
Common pitfall: A technically successful operation can still fail the patient's goal. Conversely, noncurative intent does not make every procedure futile when meaningful symptom relief is achievable.
NCI — Palliative Care in Cancer · UEMS Section of Surgery — Surgical Oncology
What to focus on during revision
The following are CertMedbry study suggestions. Use the official outline to check the full scope of your examination.
- Connect tumour anatomy, biological subtype and patient reserve before recommending an operation.
- Separate staging information from evidence that an additional intervention improves survival.
- Know the eligibility boundaries and distinct endpoints of Z0011 and MSLT-II.
- Explain the sequence and purpose of systemic treatment, surgery and radiotherapy in multimodal pathways.
- Practise absolute-effect calculations, confidence-interval interpretation and the handling of treatment switching.
- Prepare oral explanations that compare reasonable alternatives and connect decisions to patient goals.
- Use the complete official outline and curricula to extend beyond this selective guide.
A practical preparation plan
1. Build coverage across the seven written areas
Work through every domain before concentrating on specialist interests. For each concept, explain the mechanism, identify the decisive finding and state the boundary that would change management.
2. Turn each clinical principle into a decision
For a new case, state the stage or diagnostic uncertainty, treatment intent, required additional information and proposed sequence. Revisit the decision after changing one feature, such as nodal status, liver reserve or molecular sensitivity.
3. Practise structured clinical discussions
Within your declared oral specialist areas, rehearse concise case presentations followed by justified management options. Include operative extent, nonsurgical treatment, complications, functional consequences and the patient's priorities.
4. Appraise research papers aloud
Identify population, intervention, comparator, endpoint and estimand. Explain randomization, potential bias, effect size and confidence intervals, then state which patients the conclusion can reasonably inform.
5. Use the drills diagnostically
Complete the questions before reading explanations. For every error, distinguish a missing fact from a missed eligibility criterion, anatomical cue or statistical interpretation; then practise recalling the corrected reasoning with the flashcards.
6. Extend and update your preparation
Compare your coverage with the full official subject list and ESSO curricula. Read relevant disease-specific guidance and original studies, keeping historical curriculum links, current clinical evidence and examination administration dates distinct.
Use your sample score as a starting point
The free set contains 20 original practice questions. It is a small learning sample, not an official examination or a validated pass prediction. Review each explanation and its source before moving to another topic.
Start the free sampleOfficial sources and updates
- UEMS Section of Surgery — Surgical Oncology
- UEMS — Surgical Oncology EBSQ Examination
- UEMS — Surgical Oncology Curriculum and Syllabus
- ESSO — Core Curricula
- The ESSO core curriculum committee update on surgical oncology
- ASBrS — Resource Guide on Breast Cancer Breast Conservation Surgery Margins
- JAMA — ACOSOG Z0011 randomized clinical trial: 10-year overall survival
- NCI — Breast Cancer Treatment (PDQ), Health Professional Version
- NCI — Inflammatory Breast Cancer Treatment
- NCI — Melanoma Treatment (PDQ), Health Professional Version
- NCI — Sentinel Lymph Node Biopsy
- NCI — Pheochromocytoma and Paraganglioma Treatment (PDQ)
- NCI — Colon Cancer Treatment (PDQ), Health Professional Version
- NCI — Rectal Cancer Treatment (PDQ), Health Professional Version
- ICH E9 — Statistical Principles for Clinical Trials
- NCI — Gastric Cancer Treatment (PDQ), Health Professional Version
- NCI — Esophageal Cancer Treatment (PDQ), Health Professional Version
- AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma
- NCI — Primary Liver Cancer Treatment (PDQ), Health Professional Version
- NCI — Pancreatic Cancer Treatment (PDQ), Health Professional Version
- NCI — Soft Tissue Sarcoma Treatment (PDQ), Health Professional Version
- 2023 GEIS Guidelines for gastrointestinal stromal tumors
- National Library of Medicine MeSH — Numbers Needed To Treat
- FDA — E9(R1) Statistical Principles for Clinical Trials: Addendum: Estimands and Sensitivity Analysis in Clinical Trials — May 2021 final guidance
- NCI — Palliative Care in Cancer
- Completion Dissection or Observation for Sentinel-Node Metastasis in Melanoma
- ESMO-2025-Melanome.pdf
- ColoRectal_4.4.0.1.REL_CAPCP.pdf
- 2024_a-2481-7048.pdf
- HER2 Testing In Breast Cancer - 2023 Guideline Update - CAP
- 25810047.pdf
- DailyMed - YERVOY- ipilimumab injection
- A 手術｜Ⅱ章 治療法｜胃癌治療ガイドライン 第6版｜日本胃癌学会
- 7.1d%20NCCN%202.2025%20pancreatic.pdf
Confirm current eligibility, fees, scheduling and policies directly with the examination provider. CertMedbry is independent and is not endorsed by these organisations. How we handle content and corrections.